MARKET

ACIU

ACIU

AC Immune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.425
-0.015
-0.44%
Opening 10:45 08/11 EDT
OPEN
3.440
PREV CLOSE
3.440
HIGH
3.445
LOW
3.368
VOLUME
4.97K
TURNOVER
14.39K
52 WEEK HIGH
12.61
52 WEEK LOW
2.060
MARKET CAP
286.17M
P/E (TTM)
-3.4985
1D
5D
1M
3M
1Y
5Y
BRIEF-AC Immune To Present Data From Phase II Crenezumab Alzheimer’s Prevention Initiative Study
BRIEF-AC Immune To Present Data From Phase II Crenezumab Alzheimer’s Prevention Initiative Study
Reuters · 08/02 16:09
Detailed Data From Phase II Crenezumab Alzheimer's Prevention Initiative Study In Autosomal Dominant Alzheimer's Disease Presented At AAIC; Says Crenezumab Was Safe And Well Tolerated With No Cases Of ARIA-E Observed During The Up To Eight-Year Study
Crenezumab was safe and well tolerated with no cases of ARIA-E observed during the up to eight-year study As previously reported, numerical differences favoring crenezumab over placebo were confirmed across the
Benzinga · 08/02 15:02
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates
AC Immune (ACIU) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/28 12:45
AC Immune Non-GAAP EPS of -$0.23 in-line
AC Immune press release (<span class="ticker-hover-w...
Seekingalpha · 07/28 12:39
BRIEF-Ac Immune Reports Q2 2022 Financial Results
BRIEF-Ac Immune Reports Q2 2022 Financial Results
Reuters · 07/28 11:50
AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Three clinical readouts delivered year to date; four more expected by year-endFirst patient dosed with anti-Abeta vaccine ACI-24.060 in Phase 1b/2 ABATE study in patients with prodromal Alzheimer’s disease and individuals with Down syndrome Crenezumab API ...
GlobeNewswire · 07/28 11:30
AC Immune Announces Upcoming Presentations at the Alzheimer’s Association International Conference
New data from the API ADAD Study to be presented in AAIC Focused Topic SessionNew Phase 2 results from investigator-sponsored trial of the Tau PET tracer PI-2620 in Alzheimer’s disease First-time presentation of innovative biomarker-based translational cli...
GlobeNewswire · 07/22 11:30
--SVB Securities Adjusts AC Immune's Price Target to $10 from $15, Keeps Outperform Rating
MT Newswires · 07/11 10:45
More
No Data
Learn about the latest financial forecast of ACIU. Analyze the recent business situations of AC Immune through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

66.67%Strong Buy
33.33%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ACIU stock price target is 10.81 with a high estimate of 16.21 and a low estimate of 6.08.
High16.21
Average10.81
Low6.08
Current 3.425
EPS
Actual
Estimate
-0.22-0.13-0.040.05
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 55
Institutional Holdings: 14.83M
% Owned: 17.75%
Shares Outstanding: 83.55M
TypeInstitutionsShares
Increased
10
493.13K
New
3
130.56K
Decreased
13
773.34K
Sold Out
10
561.95K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.31%
Pharmaceuticals & Medical Research
-0.04%
Key Executives
Non-Executive Chairman/Independent Director
Douglas Williams
Chief Executive Officer/Co-Founder/Director
Andrea Pfeifer
Chief Financial Officer
Joerg Hornstein
Chief Operating Officer/Chief Technology Officer
Piergiorgio Donati
Chief Administrative Officer
Jean-Fabien Monin
Chief Scientific Officer
Marie Kosco-Vilbois
Other
Johannes Streffer
Non-Executive Independent Director
Monika Buetler
Non-Executive Independent Director
Alan Colowick
Non-Executive Independent Director
Thomas Graney
Non-Executive Independent Director
Carl June
Non-Executive Independent Director
Werner Lanthaler
Non-Executive Independent Director
Monica Shaw
Non-Executive Independent Director
Roy Twyman
No Data
No Data
About ACIU
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

Webull offers kinds of AC Immune SA stock information, including NASDAQ:ACIU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACIU stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACIU stock methods without spending real money on the virtual paper trading platform.